1 2 3 >  Last ›
January 6, 2021
American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols
EATONTOWN, NJ / ACCESSWIRE / January 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade. (https://www.disa.mil/about/cto/crada-process-overview) The Collaborative work will be conducted at the Biomedical Research Laboratory in Bethesda, Maryland.
December 1, 2020
American CryoStem Announces Patient Recruitment and Additional Sub-Investigator for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial
EATONTOWN, NJ / ACCESSWIRE / December 1, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has commenced recruiting subjects for its IND Phase I Clinical Trial and added an additional sub-investigator to the ATCELL™ Clinical Trial team.
September 23, 2020
American CryoStem Announces: FDA has cleared its Investigational New Drug (IND) for Post-Concussion Syndrome for Phase I Clinical Trial
EATONTOWN, NJ / ACCESSWIRE / September 23, 2020 / American CryoStem Corporation (OTC PINK:CRYO) is a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular therapy processing. The Company has developed proprietary products and services to advance its end-to-end personalized cellular therapy platform consisting of the collection - processing - cryobanking - return to point-of-care of adipose tissue and adipose-derived mesenchymal stems cells.
August 4, 2020
American CryoStem Issues Shareholder Update Letter
EATONTOWN, NJ / ACCESSWIRE / August 4, 2020 / American CryoStem Corporation (OTC PINK:CRYO) (the "Company"), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, is pleased to issue the following shareholder update letter from Chief Executive Officer John Arnone.
June 29, 2020
American CryoStem Announces the Conversion of Debenture into Equity and Sale into the Market
The debt issuance has been executed in accordance with the terms of the Debenture contained in the Company's 10-Q through the issuance of common shares in order to preserve cash available to fund ongoing operations.
April 2, 2020
American CryoStem to Develop ATCELL(TM) Clinical Study for Duchene Muscular Dystrophy with RACEMD
EATONTOWN, NJ / ACCESSWIRE / April 2, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has that it has entered into a license and collaboration agreement to apply American CryoStem technologies for the development therapy in Duchenne Muscular Dystrophy ("DMD") patients. These include autogolous (the patient's own) cell retrieval, storage, expansion and multiple administrations as well as potential use of the American CryoStem's mesenchymal stem cell product, ATCELL™. RaceMD, is a 501(c)3 charitable organization focused on the urgent development, clinical study and delivery of novel treatments to Duchene Muscular Dystrophy patients. RaceMD investigators will collaborate with CRYO laboratory staff and scientists in the development of an accelerated clinical study protocol to be filed with the US FDA.
December 5, 2019
American CryoStem Corporation Issues Shareholder Letter
EATONTOWN, NJ / ACCESSWIRE / December 5, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, issues the following letter on behalf of the CEO:
October 3, 2019
American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND
The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel suffering from concussion injury, traumatic brain injury and Post Concussion Syndrome
 1 2 3 >  Last ›